机构:[1]The Research Institute of Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu 610041, China.[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.四川大学华西医院[3]School of Laboratory Medicine, Chengdu Medical College, Chengdu 610500, China.[4]Key Laboratory of Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization, Southwest Minzu University, Chengdu 610041, China.
National Natural Science Foundation of
China (81602653) and the Fundamental Research Funds for the
Central Universities, Southwest Minzu University (2020NYBPY13,
China).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|1 区化学
小类|1 区药学
最新[2023]版:
大类|1 区医学
小类|1 区药学
第一作者:
第一作者机构:[1]The Research Institute of Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu 610041, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Tan Hong,Wang Huali,Ma Jinhu,et al.Identification of human LDHC4 as a potential target for anticancer drug discovery.[J].Acta Pharmaceutica Sinica B.2022,12(5):2348-2357.doi:10.1016/j.apsb.2021.12.002.
APA:
Tan Hong,Wang Huali,Ma Jinhu,Deng Hui,He Qinghua...&Zhang Qinglian.(2022).Identification of human LDHC4 as a potential target for anticancer drug discovery..Acta Pharmaceutica Sinica B,12,(5)
MLA:
Tan Hong,et al."Identification of human LDHC4 as a potential target for anticancer drug discovery.".Acta Pharmaceutica Sinica B 12..5(2022):2348-2357